Analgesia effects of lappaconitine in leukemia bone pain in a mouse model
- Published
- Accepted
- Subject Areas
- Animal Behavior, Neuroscience, Pharmacology
- Keywords
- Lappaconitine, leukemia, bone pain, Analgesia
- Copyright
- © 2015 Zhu et al.
- Licence
- This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, reproduction and adaptation in any medium and for any purpose provided that it is properly attributed. For attribution, the original author(s), title, publication source (PeerJ PrePrints) and either DOI or URL of the article must be cited.
- Cite this article
- 2015. Analgesia effects of lappaconitine in leukemia bone pain in a mouse model. PeerJ PrePrints 3:e971v1 https://doi.org/10.7287/peerj.preprints.971v1
Abstract
Bone pain is a common and severe symptom in cancer patients. The present study employed a mouse model of leukemia bone pain by injection K562 cells into tibia of mouse to evaluate the analgesia effects of Lappaconitine. Our results showed that the lappaconitine treatment at day 15, 17 and 19 could effectively reduce the spontaneous pain scoring values, restore reduced degree in the inclined-plate test induced by injection of K562 cells, as well as restore paw mechanical withdrawal threshold and paw withdrawal thermal latency induced by injection of K562 cells to normal group levels. Additionally, the molecular mechanisms of lappaconitine’s analgesia effects may be related to affect the expressive levels of endogenous opioid system genes (POMC, PENK and MOR), as well as apoptosis-related genes (Xiap, Smac, Bim, NF-κB and p53). Our present results indicated that lappaconitine may become a new analgesia agent for pain management induced by leukemia cells.
Author Comment
This is a revised version of a submission to PeerJ for review.